SARAH PRATT: Open Payments
NPI 1043657406 · ROCHESTER, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,571 in 132 payments from 17 companies in 2025. Trend: 2023 $1,955 · 2024 $2,375 · 2025 $2,571
Food & beverage: $2,541Education: $30
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $407 |
| Janssen Biotech, Inc. | 20 | $391 |
| Phathom Pharmaceuticals, Inc. | 20 | $280 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $276 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $201 |
| GENZYME CORPORATION | 8 | $159 |
| Ardelyx, Inc. | 6 | $149 |
| QOL Medical, LLC | 3 | $111 |
| Gilead Sciences, Inc. | 5 | $101 |
| Intercept Pharmaceuticals, Inc. | 4 | $95 |
Products named: TREMFYA, VOQUEZNA, ENTYVIO, DUPIXENT, XIFAXAN, RINVOQ, IBSRELA, Sucraid.
Industry payments across NY — which companies pay providers there.
